Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 7
2003 8
2004 5
2005 3
2007 7
2008 2
2009 5
2010 8
2011 9
2012 4
2013 5
2014 10
2015 9
2016 13
2017 12
2018 8
2019 21
2020 21
2021 37
2022 44
2023 38
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

253 results

Results by year

Filters applied: . Clear all
Page 1
Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy.
Shirasawa M, Yoshida T, Shiraishi K, Takigami A, Takayanagi D, Imabayashi T, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yotsukura M, Yoshida Y, Nakagawa K, Tsuchida T, Hamamoto R, Yamamoto N, Motoi N, Kohno T, Watanabe SI, Ohe Y. Shirasawa M, et al. Among authors: matsumoto y. Lung Cancer. 2023 May;179:107183. doi: 10.1016/j.lungcan.2023.107183. Epub 2023 Mar 25. Lung Cancer. 2023. PMID: 37037178
Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer.
Shirasawa M, Yoshida T, Shiraishi K, Goto N, Yagishita S, Imabayashi T, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yotsukura M, Yoshida Y, Nakagawa K, Naoki K, Tsuchida T, Hamamoto R, Yamamoto N, Motoi N, Kohno T, Watanabe SI, Ohe Y. Shirasawa M, et al. Among authors: matsumoto y. Br J Cancer. 2023 Dec;129(12):2003-2013. doi: 10.1038/s41416-023-02427-3. Epub 2023 Sep 20. Br J Cancer. 2023. PMID: 37731022
Kimura's Disease Diagnosed with Pleural Tumor.
Uchimura K, Imabayashi T, Matsumoto Y, Tsuchida T. Uchimura K, et al. Among authors: matsumoto y. Intern Med. 2023 Mar 1;62(5):805-806. doi: 10.2169/internalmedicine.0129-22. Epub 2022 Jul 22. Intern Med. 2023. PMID: 35871585 Free PMC article. No abstract available.
Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor.
Shinno Y, Yoshida A, Masuda K, Matsumoto Y, Okuma Y, Yoshida T, Goto Y, Horinouchi H, Yamamoto N, Yatabe Y, Ohe Y. Shinno Y, et al. Among authors: matsumoto y. Clin Lung Cancer. 2022 Jul;23(5):386-392. doi: 10.1016/j.cllc.2022.03.005. Epub 2022 Apr 29. Clin Lung Cancer. 2022. PMID: 35618627
Association of partial T2-FLAIR mismatch sign and isocitrate dehydrogenase mutation in WHO grade 4 gliomas: results from the ReSPOND consortium.
Lee MD, Patel SH, Mohan S, Akbari H, Bakas S, Nasrallah MP, Calabrese E, Rudie J, Villanueva-Meyer J, LaMontagne P, Marcus DS, Colen RR, Balana C, Choi YS, Badve C, Barnholtz-Sloan JS, Sloan AE, Booth TC, Palmer JD, Dicker AP, Flanders AE, Shi W, Griffith B, Poisson LM, Chakravarti A, Mahajan A, Chang S, Orringer D, Davatzikos C, Jain R; ReSPOND Consortium. Lee MD, et al. Neuroradiology. 2023 Sep;65(9):1343-1352. doi: 10.1007/s00234-023-03196-9. Epub 2023 Jul 19. Neuroradiology. 2023. PMID: 37468750
δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion.
Shimizu T, Ishida J, Kurozumi K, Ichikawa T, Otani Y, Oka T, Tomita Y, Hattori Y, Uneda A, Matsumoto Y, Date I. Shimizu T, et al. Among authors: matsumoto y. Mol Cancer Ther. 2019 Apr;18(4):812-822. doi: 10.1158/1535-7163.MCT-18-0138. Epub 2019 Mar 14. Mol Cancer Ther. 2019. PMID: 30872378
253 results